장질환 검사 시장 예측(-2030년) - 병원균별, 기술별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Enteric Disease Testing Market is accounted for $4.18 billion in 2023 and is expected to reach $7.16 billion by 2030 growing at a CAGR of 8% during the forecast period. Infections of the gastrointestinal tract, including the stomach, small intestine, and large intestine, are known as enteric diseases. Microorganisms such as bacteria, viruses, and parasites can cause these disorders. Clostridium difficile (C. difficile), campylobacteriosis, cholera, Escherichia coli (E. coli), Helicobacter pylori (H. pylori), salmonellosis, shigellosis, norovirus, rotavirus, amebiasis, cryptosporidiosis, and giardiasis are some typical instances of enteric disorders.

According to the World Health Organization (WHO) report published in May 2020, foodborne diseases can be severe, especially for young children. According to the same source, diarrheal diseases are the most common illnesses resulting from unsafe food, with 550 million people falling ill yearly, of which 220 million are children under the age of 5 years.

Market Dynamics:

Driver:

Increase in demand for convenience foods

Busy lives have gradually altered customer focus away from traditional raw food purchases and toward convenience and packaged foods such as frozen foods and ready-to-eat (RTE) meals. To increase marketability, chemicals are employed to enhance the organoleptic properties of food and beverages. However, preservatives are also applied to packaged products to extend their shelf life.

Restraint:

High cost

Automated testing instruments are expensive because they include extensive features and functions. The cost of spectroscopy-based systems, for example, ranges from USD 150,000 to USD 850,000. For some end users, the estimated cost of the instrument, media, and labor is also very high.

Opportunity:

Technological advancements

Technological developments and innovation throughout the supply chain have changed the way business operates. The emphasis is on decreasing lead time, sample utilization, and the overall cost of testing services provided. In the enteric illness market, cheaper, faster, and more efficient computing technology, combined with improved software, network connectivity, and smart sensors, is gaining attraction.

Threat:

Lack of proper regulations

The food business in underdeveloped nations is still extremely fragmented, dominated by small and unorganized firms that may not have implemented basic food testing standards, posing a higher risk of contamination. Food and beverage product testing, such as packaged foods, dairy products, beverages, and meat products, necessitates appropriate enforcement mechanisms, coordination among market parties, and supporting infrastructure. However, many nations in the developing economies cluster lack these variables, limiting pathogen testing in food and water in these locations.

COVID-19 Impact:

People were concerned about viral and bacterial contamination during the COVID-19 pandemic, so they opted for home-cooked or clean cuisine. This resulted in a decreased infection rate and a decrease in the number of tests performed in 2020 and 2021. Also, during the pandemic, COVID-19 testing took precedence over all other infectious disease testing; hence, demand for enteric illness testing kits decreased during the pandemic, hampering market growth.

The food segment is expected to be the largest during the forecast period:

Food segment is expected to hold largest share throughout the projected period with the expansion of the food trade, public health, and government organizations have been driven to regularly check food quality and take immediate action to identify, contain, and correct outbreak origins. For example, the Enteric Disease and Inspection Service (FSIS) has developed regulations based on the HACCP enteric disease control system to limit the contamination of meat and poultry products in slaughterhouses and processing plants.

The rapid technology segment is expected to have the highest CAGR during the forecast period:

Rapid technology segment is expected to have lucrative growth during the forecasted period. It is used in the food industry to monitor the number, type, and metabolites of microorganisms that cause food spoilage, preservation, fermentation, safety, and foodborne pathogens. The use of the Hazard Analysis and Critical Control Points (HACCP) model and other enteric disease systems has become firmly entrenched in quality assurance and quality control (QA/QC) programs, as has the industry's requirement for "faster, better, cheaper" real-time results from tests.

Region with largest share:

North America dominated the enteric disease testing market in 2022 and is likely to continue to do so during the forecast period. The presence of several major players in the region, such as Abbott Laboratories, Becton Dickinson & Company, Biomerica, Inc., Bio-Rad Laboratories, Inc., Meridian Bioscience, Inc., and Quest Diagnostics, as well as advancements in the manufacturing technology of enteric disease testing products, drive the market's growth. This is mostly due to an increase in the number of people suffering from enteric diseases, an increase in government financing for enteric disease diagnosis research, and a considerable increase in capital income in industrialized nations.

Region with highest CAGR:

Due to an increase in the prevalence of infectious enteric diseases such as E. coli, salmonellosis, cholera, and H. pylori in this region, as well as growth in the purchasing power of populated countries such as China and India, Asia-Pacific is expected to grow at the highest pace during the enteric disease testing market forecast period. Additionally, attractive market regions are located in growing countries such as China and India, driving Asia Pacific's most rapid growth. Asia-Pacific is predicted to develop most rapidly, owing to increased testing awareness and rising ailments.

Key players in the market

Some of the key players in Enteric Disease Testing market include Merck KGaA , Thermo Fisher Scientific Inc., SGS SA, Eurofins Scientific, Bureau Veritas, Intertek, Romer Labs, Merieux NutriSciences, TUV SUD, PerkinElmer, Inc, Becton Dickinson, Certified Laboratories, ALS Limited, Neogen Corporation and Hardy Diagnostics.

Key Developments:

In January 2022, Meridian Bioscience Inc. announced that the Curian Campy assay has received U.S. Food and Drug Administration (FDA) clearance. The Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a Campylobacter-specific antigen including C. jejuni, C. coli, C. upsaliensis, and C. lari in human fecal specimens. The assay was developed to be utilized on the Curian immunofluorescent testing platform.

In January 2020, Biomerieux SA announced that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE BCID Panel.

Pathogens Covered:

• Campylobacter
• Clostridium
• E. coli
• Enterobacteriaceae
• Hepatitis A, B, and E
• Listeria
• Norovirus
• Rotavirus
• Salmonella
• Shigella
• Vibrio
• Other Pathogens

Technologies Covered:

• Traditional
• Rapid
• Convenience Based
• Polymerase Chain Reaction (PCR)
• Immunoassay
• Chromatography & Spectrometry
• Other Technologies

End Users Covered:

• Water
• Food
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Enteric Disease Testing Market, By Pathogen

• 5.1 Introduction
• 5.2 Campylobacter
• 5.3 Clostridium
• 5.4 E. coli
• 5.5 Enterobacteriaceae
• 5.6 Hepatitis A, B, and E
• 5.7 Listeria
• 5.8 Norovirus
• 5.9 Rotavirus
• 5.10 Salmonella
• 5.11 Shigella
• 5.12 Vibrio
• 5.13 Other Pathogens

6 Global Enteric Disease Testing Market, By Technology

• 6.1 Introduction
• 6.2 Traditional
• 6.3 Rapid
• 6.4 Convenience Based
• 6.5 Polymerase Chain Reaction (PCR)
• 6.6 Immunoassay
• 6.7 Chromatography & Spectrometry
• 6.8 Other Technologies

7 Global Enteric Disease Testing Market, By End User

• 7.1 Introduction
• 7.2 Water
• 7.3 Food
  • 7.3.1 Meat, Poultry and Seafood
  • 7.3.2 Dairy Products
  • 7.3.3 Processed Food
  • 7.3.4 Fruits & Vegetables
  • 7.3.5 Nuts, Herbs & Spices
  • 7.3.6 Cereals & Grains
  • 7.3.7 Other Foods
• 7.4 Other End Users

8 Global Enteric Disease Testing Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Merck KGaA
• 10.2 Thermo Fisher Scientific Inc.
• 10.3 SGS SA
• 10.4 Eurofins Scientific
• 10.5 Bureau Veritas
• 10.6 Intertek
• 10.7 Romer Labs
• 10.8 Merieux NutriSciences
• 10.9 TUV SUD
• 10.10 PerkinElmer, Inc
• 10.11 Becton Dickinson
• 10.12 Certified Laboratories
• 10.13 ALS Limited
• 10.14 Neogen Corporation
• 10.15 Hardy Diagnostics